Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Exact Sciences Preliminary Q4 Revenues Beat Estimates

Exact Sciences Preliminary Q4 Revenues Beat Estimates

Jan 12, 2020
|
staff reporter

NEW YORK – Exact Sciences on Sunday said that it expects to report fourth quarter revenues of between $294 million and $296 million, well above its previously stated estimate of $232.8 million and the consensus Wall Street estimate of $253.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Working Out the Effect

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Increased Genetic Privacy in Florida

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

Attention-Grabbing in Two Ways

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

Nature Papers Describe CRISPR Plant Editing Methods, DNA-PAINT Improvements, More

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.

What's Popular?

In Business News

  1. Surge in Stocks of SARS-CoV-2 Dx Developers Pushes GenomeWeb Index Up 15 Percent in H1 2020

  2. FDA Issues Warning Letter to Luminex

  3. Invitae Stock Skyrockets in June on ArcherDx Acquisition, Leading GenomeWeb Index

  4. Centogene Gets Emergency Use Authorization for PCR-Based Coronavirus Test

  5. Sherlock Biosciences, Binx Health Partner to Develop CRISPR-Based POC COVID-19 Test

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.